Clinical Study
Effect of HSV-2 Suppressive Therapy on Genital Tract HIV-1 RNA Shedding among Women on HAART: A Pilot Randomized Controlled Trial
Table 3
Primary and secondary outcomes analysis.
| Acyclovir versus control | OR (95% CI) | value |
| GT HIV-1 RNA | | | Detection | 1.23 (0.47, 3.20) | 0.67 | Quantity | 0.92 (0.28, 3.06) | 0.90 | Detection when PVL is undetectable | 0.42 (0.17, 1.06) | 0.07 | Quantity when PVL is undetectable | 0.34 (0.11, 1.05) | 0.06 | HSV DNA | | | Detection | 0.38 (0.15, 0.99) | <0.05 | Plasma HIV-1 RNA | | | Detection | 1.93 (0.66, 5.68) | 0.23 | Quantity | 3.33 (0.61, 16.67) | 0.17 | Adherence | | | Three-day nonadherence to HAART | 0.93 (0.47, 1.86) | 0.84 | Two-week nonadherence to HAART | 1.30 (0.59, 2.87) | 0.51 |
|
|
NOTE. GT, Genital Tract; RNA, ribonucleic acid; PVL, plasma viral load; HSV, herpes simplex virus; DNA, deoxyribonucleic acid; HAART, highly active antiretroviral therapy.
|